Amanta Healthcare Ltd
Amanta Healthcare Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
SteriPort line commissioning expected by June 20, 2026, adding INR 80-85 crore in revenue for FY27 (three quarters), with full INR 110-120 crore impact in FY28. FY26 PAT margin stood at 5%, with PAT growing 42% YoY, supported by better operating leverage and reduced finance cost.
From Amanta Healthcare Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- SteriPort line commissioning expected by June 20, 2026, adding INR 80-85 crore in revenue for FY27 (three quarters), with full INR 110-120 crore impact in FY28.
- New product pipeline of 20 products in inhalation and ophthalmic segments to commercialize in FY27-28, supporting growth.
- Export revenue grew from 32% in FY25 to 39% in FY26; active marketing in 25-30 countries with key markets including UK, Thailand, Philippines, South Sudan.
- Export markets like East Africa show cyclical buying patterns; export sales generally stronger in H2.
- Domestic IV fluid demand growing at 8-10% year-on-year, with two-port systems growing faster at 12-13%.
- Capacity ramp-up expected to reach full utilization within 3-4 months post commissioning, driving scale and margin expansion.
- Solar power project to reduce costs and boost profitability from FY27 onwards.
- Overall, growth driven by capacity expansion, new specialized products, and export market expansion.
Profitability & Margins
See what Amanta Healthcare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Amanta Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Amanta Healthcare Limited does not maintain a long-term order book extending over one year.
- Export orders are rolling and cyclic, with visibility of around 3 to 6 months in some markets.
- For example, the East African market's significant purchases happen from September to March, and export numbers tend to be better in H2 than H1.
- Markets like Southeast Asia show consistent order patterns throughout the year.
- The management currently does not have exact quantified numbers for the next quarter's order book but may share it separately.
- The company operates primarily on distributor-based orders rather than fixed long-term contracts.
Amanta Healthcare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹77 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Amanta Healthcare Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Torrent Pharmaceuticals Ltd (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
- Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
- RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
- Sai Parenteral's (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…
Frequently Asked Questions
What were Amanta Healthcare Ltd Q4 FY26 results?
SteriPort line commissioning expected by June 20, 2026, adding INR 80-85 crore in revenue for FY27 (three quarters), with full INR 110-120 crore impact in FY28. FY26 PAT margin stood at 5%, with PAT growing 42% YoY, supported by better operating leverage and reduced finance cost.
What is Amanta Healthcare Ltd share price analysis?
Amanta Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 39.6 with a market cap of ₹607 Cr. Investors should review the full earnings analysis for detailed insights.
Is Amanta Healthcare Ltd planning capital expenditure?
SteriPort expansion: Commissioning expected by June 2026, aiming for operational by June 20; will add approx.
Keep Amanta Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.